2023-04-14 07:24:52 ET
- Mind Medicine ( NASDAQ: MNMD ) added 10% after announcing that an investigator-initiated mid-stage trial for a depression therapy reached the primary endpoint with a statistically significant improvement in disease symptoms.
- The double-blind, active-controlled study was designed to evaluate the safety and efficacy of lysergide, a compound related to the company’s lead candidate MM-120, in 61 patients with major depressive disorder (MDD).
- According to its topline data, there were statistically and clinically significant improvements in the primary endpoint in patients who received the high-dose lysergide regimen compared to the control, six weeks after the first administration.
- “These positive findings are particularly relevant to our MM-120 program in generalized anxiety disorder, given the high degree of comorbidity of GAD and MDD,” Robert Barrow, Chief Executive Officer of Mind Medicine ( MNMD ), said.
- According to Seeking Alpha analyst Gary Bourgeault MNMD could present a compelling entry point as a short-term play.
For further details see:
MindMed gains 10% as mid-stage depression trial meets key goal